Faster testing could allow more people to return to work or permit
testing on entry to hospital, thus slowing a second spike in
coronavirus infections.
The new test, based on the design of a DNA test developed by a
professor at Imperial College London, received approval for clinical
use by the Medicines and Healthcare Products Regulatory Agency (MHRA)
at the end of April after successful trials.
In a study in The Lancet Microbe, the test was found to have an
average sensitivity – the ability to correctly identify those with
COVID-19 – of 94.4% and a specificity – correctly identifying those
without the disease – of 100%.
"These results suggest that the CovidNudge test, which can be
performed at a patient’s bedside without the need to handle any
sample material, has comparable accuracy to standard laboratory
testing," Professor Graham Cooke, lead author of the study from the
Department of Infectious Disease at Imperial College London, said.
The Lancet paper described the test, which requires one nostril swab, as "a
sensitive, specific, and rapid point of care test for the presence of SARS-CoV-2
without laboratory handling or sample pre-processing".
[to top of second column] |
Health Secretary Matt Hancock told LBC radio that Britain was rolling out the
tests across hospitals.
"The critical thing in terms of usefulness is that the machine doesn't need to
be in a lab - it is about the size of a shoebox - therefore you can put one,
say, in an A&E (accident and emergency) department and they can know whether
people coming in have got the coronavirus or not," Hancock said.
Hancock said the machines could also be deployed at other locations such as
schools.
Each box can run one test at a time so could process about 16 tests per day,
said a spokeswoman for the company that produces the tests.
For the text of the Lancet paper:
https://www.thelancet.com/
journals/lanmic/article/PIIS2666-5247(20)30121-X/fulltext
(Reporting by Guy Faulconbridge; editing by Kate Holton and Gareth Jones)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |